Back to top

HIV prevention efforts have seen remarkable breakthroughs over the last few years, among the latest being the U.S. Food and Drug Administration (FDA) approval of long-acting lenacapavir (LEN), the six-month pair of injections marketed as Yeztugo in the states. But having the products is not necessarily good enough if they aren’t delivered and available to the people who need them. One symposium at the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda, explored ways of moving medications efficiently to implementation faster and cheaper. A new funding crisis has hit countries most in need of PrEP services, just as new LEN is about to roll out, meaning that stakeholders, policy makers and drug manufacturers must do more to ensure equitable access worldwide, presenters said. And they said health policy advocates and even health care systems and clinics have a role as well. Several presenters shared lessons learned from different aspects of PrEP rollout, from oral to long-acting options. 

Affordability and price transparency needed urgently

Anne-Isabelle Cameron, a technical officer at UNITAID, a global effort that works with low- and middle-income countries, told attendees that affordability, price transparency and restricted access to generic drugs remain challenges to scaling up PrEP worldwide. Citing data from PrEPWatch, she estimated the cost of oral PrEP to be $40 per year, the dapivirine vaginal ring at $154 and injectable cabotegravir (CAB-LA) $180 yearly. Cameron decried the fact that long-acting PrEP options are four times as expensive as oral PrEP.

“The price for long-acting lenacapavir remains unknown, causing great challenges for countries to plan accordingly,” she said. “And this includes the middle-income countries, where about one in every four new infections that occur face the double burden of not having access to the lowest originator price, nor being included in the voluntary licensed territory, and therefore not having access to generics.”

These barriers are all the more challenging in the current context of funding interruptions and pullbacks. International assistance accounted for about 80% of prevention programs in low- and middle-income countries, with three more countries—Malawi, Nigeria and Zimbabwe—relying on aid from the U.S. through PEPFAR for more than 70% of their HIV funding as of December 2024. “[Cuts have] led to interrupted services, in particular for key and other vulnerable populations, the exclusion of prevention programs, fragile markets and barriers to economies of scale. UNAIDS figures show that estimated new daily HIV infections have risen from 3,500 per day to 5,800, and that if funding permanently disappears, there could be potentially an additional 6 million infections by 2029 and an additional 4 million AIDS-related deaths.”

What’s needed, Cameron said, is for drug companies to speed up the pathways to generic medications and equitable access to PrEP. Communities, governments and partner organizations have a role to play as well, she said, in community engagement and demand generation and informing real-time rollout. 

UNITAID is seeking investments through a call for proposals for cost effective and high impact rollout of LEN for PrEP.

Cameron also shared some encouraging news: studies have shown that with strategic interventions, long-acting lenacapavir could be an affordable option. One analysis concludes that LEN could be manufactured and delivered for as low as $35 per year at two million treatments annually and as low as $25 per year for five to 10 million people.

Also in the session, Michelle Rudolph of the World Health Organization shared the recently issued WHO guidelines on lenacapavir for PrEP. She reported that as of 2024, 94% of countries worldwide have adopted WHO recommendations on oral PrEP in their national guidelines; only 12 countries adopted policies for CAB and 10 countries have adopted policies for the dapivirine vaginal ring. “Ten countries reported that their national guidelines do not recommend any PrEP products,” she said.

For LEN rollout, Rudolph emphasized the importance of provider training. “We are in a place right now where we no longer have boutique key population clinics. We are going to have to look at the existing services and how we can make them more accessible and acceptable to key populations and other people who do not always access those services. [And we need to] train providers to offer this product, and to be comfortable offering clients a choice and to not judge them and encourage them along their prevention journey.”

Project PrEP: Service delivery that young people prefer

Saiqa Mullick, MPH, MSc, PhD, a professor with the University of Witwatersrand in Johannesburg, prefaced her presentation by offering a lesson from the rollout of CAB: “Product innovation has to be matched with delivery innovation.”

Dr. Mullick shared ongoing research and lessons from Project PrEP, a UNITAID-funded initiative aimed at integrating PrEP into comprehensive sexual and reproductive health services for adolescent girls and young women.

“Project PrEP uses a differentiated service delivery model designed to meet young people where they are,” she said. “Services are anchored in fixed health department clinics across three geographic areas. But we go beyond that by extending access through youth-friendly mobile clinics and PrEP pick-up points in community-based organizations and community pharmacies wherever possible.” This mix of fixed and flexible delivery helps reduce some of the access barriers, increases convenience and supports young people to engage with HIV prevention in ways that fit their lives, she said.

The first lesson from the interim analysis was that young people prefer long-acting PrEP when it’s offered. In a study conducted April–November 2024, students were asked which form of PrEP they preferred—oral PrEP, a vaginal ring or CAB-LA. Overall, 65% of students chose CAB-LA; that included 80% of women over age 24 and 73% of males over age 15.

“It’s clear that no single PrEP method fits everyone’s needs all the time,” Mullick said. 

Researchers also learned that long-acting PrEP can increase protection. “People stayed on injectable PrEP longer [than oral PrEP] before stopping.” And the restart rate was much higher for CAB than for oral PrEP.   

Interim analysis from Project PrEP also showed that integration creates efficiency. Among participants who selected a PrEP method at enrollment, the vast majority were also screened for STI symptoms, TB, mental health needs and gender-based violence. Of the 3,000 women who chose a PrEP method, 76% were either already using a contraceptive or received one during that visit; nearly half of the women received their contraception on the same day as their PrEP appointment. “This tells us that same-place delivery of prevention and sexual and reproductive health care is feasible and valued.”

Dr. Mullick said that delivery platform readiness is also crucial. Researchers spoke with 34 healthcare providers across three districts in South Africa to understand what’s helping or hindering delivery of PrEP. “Providers emphasized the importance of consistent, clear messaging throughout the client journey, supported by tools like pamphlets, models and demonstration products. Just as important was a provider’s positive attitude, ongoing learning and tailored training for different roles.”

But there were real challenges, too: time and space constraints, a perceived increase in workload and missed follow-up visits that disrupted continuity of care. “Some providers and clients also expressed uncertainty or mistrust of newer methods, showing us that both confidence and capacity need to be built as we introduce innovative options like lenacapavir. If we want providers to enable informed choice, we need to invest in them just as much as we invest in products.”

Dr. Mullick added that counseling is fundamental, especially when reaching adolescents and young women. “Women respond positively when they’re shown different options using visual tools and simple, relatable language, not clinical jargon. They value providers who take time to answer questions honestly and maintain privacy, but when counseling feels rushed, judgmental or confusing, it becomes a barrier.”

She said that community awareness and PrEP literacy and engagement are essential. “That means working closely with community-based organizations.” Concluding, Dr. Mullick said that product innovation is also important. 

“People want convenience, autonomy and digital connection,” she said. Researchers found that digital platforms, especially online and social media, were preferred over printed materials for HIV information. For picking up meds, pharmacies, home delivery and vending machines were far more popular than clinics. Most people wanted twice-yearly visits rather than quarterly ones, and they strongly preferred self-testing over provider testing, suggesting “a real desire for privacy and control,” Dr. Mullick said. 

“Interestingly, pop-up sites were the least preferred for PrEP initiation. People still value trusted, familiar spaces like pharmacies and clinics, and these preferences are a clear guidepost as we think about how to deliver them and other new PrEP options in ways that people will actually use.”

South Africa’s PrEP journey

South Africa remains the epicenter of the HIV epidemic, with an estimated 400 new cases each day, with transgender individuals, gay and bisexual men and people who engage in sex work making up a disproportionate majority. 

Hasina Subedar, a senior technical advisor at South Africa’s National Department of Health, told conference participants that PrEP uptake in the country was notably higher at sites where all options (CAB, oral PrEP and the vaginal ring) were available. She also reported surprising findings about long-acting cabotegravir: across South Africa, CAB uptake is highest among young women age 20–34; despite earlier concerns, CAB injections were seen as practical in mobile clinics, with no major logistical challenges with transportation or storage.

The main challenge in HIV prevention, Subedar said, has been continued use of oral PrEP while rolling out long-acting options.

“Keeping people on oral PrEP has been a challenge, and many users drop off within months. Equity is uneven. Even though we’ve reached—and we try to reach—all populations, uptake among men and key populations, and service quality, varies across provinces and districts,” she said. 

Despite having a significant (though improving) burden of HIV, South Africa is well positioned to roll out and scale up long-acting PrEP options, Subedar said. Since 2021, oral PrEP has been financed nationally, which shields the country from PEPFAR cuts. South Africa also has a nurse-initiated antiretroviral drug program, and same-day initiation is now a routine option. “Every single primary healthcare clinic [has] nurses that can initiate data integration; that has been key, especially where PrEP metrics are alongside the ART [antiretroviral therapy] metrics.” 

She concluded by saying that South Africa’s successes show that scale, integration and equity are achievable. “We must shift from isolated product rollouts to build a comprehensive HIV prevention ecosystem that ensures choice, equity, dignity and sustainable financing for all.”

Encouraging results from monthly oral PrEP (MK-8527)

Amid the enthusiasm for twice-yearly Yeztugo, health care providers are also pinning their hopes on longer-acting tablets for PrEP, which may be easier to roll out than injectables. Right now, there are no approved oral PrEP medications to be taken less frequently than once daily. But that may change.

MK-8527 is a novel nucleoside reverse transcriptase translocation inhibitor (NRTTI) and works differently from NRTIs by stopping the movement of the reverse transcriptase enzyme and by blocking HIV from copying its RNA to DNA. In 2021 drugmaker Merck’s first NRTTI candidate for long-acting treatment and prevention, islatravir, was tabled after some study participants experienced declining CD4 T cell or total lymphocyte counts with higher doses. 

MK-8527 study participants were determined to be at low risk for HIV exposure and randomly assigned to receive the drug at 3 mg, 6 mg or 12 mg doses (or a placebo) monthly for up to six months. Presenting safety and PK data from a phase 2 study for MK-8527, Kenneth Mayer, MD, FACP, FIDSA, of Fenway Health and Harvard Medical School, said all dosing levels were well tolerated, with most common adverse events being mild-to-moderate headache, nausea and fatigue. MK-8527 had a similar profile to the placebo group. There were no HIV seroconversions in any group.

The drug had a “rapid onset” of protection, reaching full protective levels within 24 hours, Dr. Mayer said. In the 6 mg and 12 mg dose groups, drug concentrations were sustained above the threshold for protection for a little longer than 28 days, which is helpful if people are late with dosing. He cautioned that drug levels declined after 40 days, making the drug unsuitable for use as an every-other-month option. Importantly, participants did not experience a decline in CD4 cell or total lymphocyte counts. Based on the phase 2 findings, Merck will move MK-8527 into phase 3 trials, in partnership with the Gates Foundation and the International Clinical Research Center at the University of Washington.

In another session, Rebeca Plank, MD, MPH, of MSD Research Laboratories, said that once-monthly oral PrEP options could “represent a paradigm shift” by making it easier for people to obtain and to take PrEP. “This would allow more people to start and to continue on PrEP, ultimately helping us reach our collective goal of ending the epidemic,” she said.

LARRY BUHL is a multimedia journalist based in Los Angeles. He has covered HIV/AIDS and other infectious diseases for more than two decades. In addition to POSITIVELY AWARE, he is a regular contributor to TheBody.com, Everyday Health and capitalandmain.com. His work has appeared in USA Today, Salon, Undark, KQED, The New York Times and others.